USFDA flags CGMP lapses at Dabur’s Silvassa plant; import alert remains in force
USFDA has issued a warning letter to Dabur India citing data-integrity, quality-control and manufacturing deficiencies at its Silvassa pharmaceutical facility. The plant remains on Import Alert 66-40 after a partial voluntary US recall, raising compliance and export-continuity risks.
USFDA issued Dabur India a warning letter over data integrity, quality-control and manufacturing lapses at its Silvassa pharmaceutical plant. The facility’s products remain under Import Alert 66-40, following a partial voluntary US recall and regulator demands for corrective action.
Why this matters
The compliance action follows recent Dabur signals on FSSAI's disputed '100%' claims, label updates and analysts' hold recommendations, adding regulatory and export risk to the brand's outlook.
Retail-company signals are accelerating, up 164222% QoQ.